Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1

European Journal of Heart Failure

Volumn 12, Issue 2, 2010, Pages 193-196

  Lainscak, Mitja ^a,b   Coletta, Alison P ^c   Sherwi, Nasser ^c   Cleland, John G F ^c  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; Randomized controlled trials

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FUROSEMIDE; GALECTIN 3; TECHNETIUM 99M;

AGE DISTRIBUTION; BODY MASS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR EFFECT; CELL TRANSPLANTATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE PERFUSION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOKALEMIA; IMAGING; IMPEDANCE; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIVER CONGESTION; LOW DRUG DOSE; MEASUREMENT; MYOBLAST; MYOCARDIAL PERFUSION IMAGING; OXYGEN SATURATION; PATIENT EDUCATION; PATIENT SAFETY; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RENAL PROTECTION; RISK ASSESSMENT; SEX DIFFERENCE; SYSTOLIC HEART FAILURE; THORAX IMPEDANCE; WEIGHT;

AGED; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DOPAMINE; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOBLASTS; MYOCARDIAL PERFUSION IMAGING; RISK ASSESSMENT; SOCIETIES, MEDICAL;

EID: 75149130005     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp185     Document Type: Conference Paper

References (30)

1. Braunschweig F, Fahrleitner-Pammer A, Mangiavacchi M, Ghio S, Fotuhi P, Hoppe UC, Linde C. Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. Eur J Heart Fail 2006;8:797-803.
2. Freemantle N, Tharmanathan P, Calvert MJ, Abraham WT, Ghosh J, Cleland JG. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction-a systematic review and meta-analysis. Eur J Heart Fail 2006;8:433-440.
3. Zhang J, Goode KM, Cuddihy PE, Cleland JGF, on behalf of the TEN-HMS Investigators. Predicting hospitalization due to worsening heart failure using daily weight measurement: analysis of the Trans-European Network-Home-Care Management System (TEN-HMS) study. Eur J Heart Fail 2009;11:420-427.
4. Lainscak M, Cleland JG, Lenzen MJ, Nabb S, Keber I, Follath F, Komajda M, Swedberg K. Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysis. Eur J Heart Fail 2007;9: 1095-1103.
5. Braunschweig F, Ford I, Conraads V, Cowie MR, Jondeau G, Kautzner J, Lunati M, Munoz Aguilera R, Man Yu C, Marijianowski M, Borggrefe M, van Veldhuisen DJ, DOT-HF steering committee investigators. Can monitoring of intrathoracic impedance reduce morbidity and mortality in patients with chronic heart failure? Rationale and design of the Diagnostic Outcome Trial in Heart Failure (DOT-HF). Eur J Heart Fail 2008;10:907-916.
6. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008;10:933-989.
7. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe; part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463. (Pubitemid 36286187)
8. Lainscak M, Moullet C, Schön N, Tendera M. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol 2007;122:149-155.
9. de Groote P, Isnard R, Clerson P, Jondeau G, Galinier M, Assyag P, Demil N, Ducardonnet A, Thebaut JF, Komajda M. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. Eur J Heart Fail 2009;11:85-91.
10. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Tavazzi L, Poole-Wilson PA, Le Pen C. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005;26:1653-1659.
11. Granger BB, Swedberg K, Eckman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA, CHARM investigators. Adherence to candesar-tan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled trial. Lancet 2005;366:2005-2011.
12. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, Mehra M, O'Connor CM, Reynolds D, Walsh MN. Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. Am Heart J 2007;154:12-38.
13. https://www.improvehf.com (12 October 2009).
14. Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol 2009;132:303-311.
15. De Boer RA, Voors AA, Muntendam P, van Gilst WH, van Velduisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811-817.
16. Jaarsma T, Van Der Wal MH, Hogenhuis J, Lesman I, Luttik MLA, Veeger NJGM, van Veldhuisen DJ. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart Failure. Eur J Heart Fail 2004;6:227-233.
17. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJ, Dunselamn PH, Tilssen JG, Hilledge HL, van Veldhuisen DJ. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study on Outcomes of Advising and Counselling in Heart Failure (COACH). Arch Intern Med 2008;168:316-324.
18. Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, Körfer R, Klein M, Krahn T, Kruska L, El Banayosy A, Kramer F. Plasma biomarkers of myo-cardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008;27:589-596.
19. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Mcfarlane PW, Murray GD, Mule JD, Vered Z, Lahiri A, for the CHRISTMAS investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial) randomised controlled trial. Lancet 2003;362:14-21.
20. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Piña IL, HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439-1450.
21. Coletta AP, Cleland JGF, Cullington D, Clark AL. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur J Heart Fail 2008;10:917-920.
22. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008;10:188-195.
23. Kaminski K, Goode KM, Clark AL, Cleland JGF. The effect of transient changes in laboratory parameters on distant mortality of patients hospitalized for heart failure. Eur Heart J 2009;30(Abstract Suppl.):139.
24. Cleland JGF, Coletta AP, Yassin A, Buga L, Torabi A, Clark AL. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE I, European CRT survey, German pre-SCD II registry and MADIT-CRT. Eur J Heart Fail 2009;11:1214-1219.
25. Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med 2002;28: 877-883.
26. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopa-mine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005;142:510-524.
27. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008;117:200-205.
28. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagège AA. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008;117:1189-1200.
29. Menasché P. Stem cell therapy for heart failure: are arrhythmias a real safety concern? Circulation 2009;119:2735-2740.
30. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implan-table cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.